Translate 
Abstract
Postpartum depression (PPD), the most common childbirth complication in the United States, can be treated using brexanolone, an intravenous form of allopregnanolone. This retrospective chart review study evaluated clinical outcomes of 64 postpartum women who received brexanolone infusion for PPD in a real-world setting. Treatment was associated with improved depression and anxiety symptoms, and 71% of patients reported significant improvement in their PPD. While further research is needed, this study supports brexanolone as an efficacious treatment for PPD.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
